GSK's $750M Trispecific TCE Bet: Safety Hypothesis Without Clinical Proof in a Crowded Myeloma Field

GSK Acquires Preclinical Trispecific T Cell Engager for Multiple Myeloma

GSK has acquired a preclinical trispecific T cell engager program from China biotech Chimagen Biosciences in a deal potentially worth up to $750 million. The British pharma will pay an an undisclosed upfront fee for full global rights to the candidate, which is expected to enter the clinic for multiple myeloma next year. This marks GSK's second deal with Chimagen, following a 2024 pact for a separate T cell engager targeting B cell-mediated conditions, valued at up to $850 million. The newly acquired TCE aims to offer differentiated efficacy and a better safety profile compared to existing bispecific T cell engagers for multiple myeloma, which carry boxed warnings for cytokine release syndrome and neurologic toxicity.

• GSK has secured full global rights to a preclinical trispecific T cell engager from Chimagen Biosciences, with the deal potentially reaching $750 million through undisclosed development and commercial milestone payments, in addition to an upfront fee. This acquisition strengthens GSK's oncology pipeline, particularly in multiple myeloma, by adding a novel therapeutic approach.
• The acquired trispecific T cell engager is designed to target T cells and two tumor antigens, aiming to provide superior efficacy and an improved safety profile compared to current bispecific T cell engagers approved for multiple myeloma. Existing treatments like J&J's Tecvayli and Talvey, Regeneron's Lynozyfic, and Pfizer's Elrexfio are associated with boxed warnings for cytokine release syndrome and neurologic toxicity, which this new candidate seeks to mitigate.
• This agreement represents GSK's second collaboration with Chimagen, building on a 2024 deal worth up to $850 million for CMG1A46, a bispecific T cell engager currently in Phase 1 trials for B cell malignancies and autoimmune disorders. The new program is expected to enter clinical development for multiple myeloma next year, further diversifying GSK's oncology portfolio and addressing unmet patient needs.

The Emerging Promise of Trispecific T Cell Engagers in Multiple Myeloma

The treatment landscape for multiple myeloma has undergone substantial evolution over the past three years, with several mechanistically distinct therapeutic strategies advancing through clinical development. These approaches collectively aim to overcome resistance to established agents and achieve deeper, more durable responses — including sustained MRD negativity — in both newly diagnosed and relapsed/refractory settings.

• Cereblon E3 Ligase Modulators (CELMoDs): Next-generation CELMoDs, including mezigdomide (CC-92480) and iberdomide (CC-220), represent a mechanistic evolution beyond IMiDs such as lenalidomide and pomalidomide. These agents alter the conformation of cereblon within the CRL4CRBN E3 ubiquitin ligase complex, recruiting Ikaros (IKZF1) and Aiolos (IKZF3) for selective proteasomal degradation. Mezigdomide exhibits the greatest cereblon-binding potency among CELMoDs and demonstrates anti-proliferative, apoptotic, and immune-stimulatory effects, including activity in lenalidomide- and pomalidomide-resistant MM cell lines.

• BCMA-Targeted Immunotherapies — CAR-T Cells and Bispecific Antibodies: BCMA-directed CAR-T cell therapies, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have demonstrated high response rates in relapsed/refractory MM. A meta-analysis of 44 cohorts (1,833 patients) reported a pooled ORR of 89% (95% CI: 82–93) and CR rate of 57% (95% CI: 47–66) for autologous BCMA-directed CAR-T. Bispecific strategies — including BCMA/CD19-directed CAR-T (ORR 92%, 95% CI: 89–95; CR rate 64%, 95% CI: 16–94) and BCMA/CD38-directed CAR-T (ORR 88%, 95% CI: 82–93; CR rate 61%, 95% CI: 22–90) — show particularly encouraging depth of remission. Bispecific T cell engagers such as teclistamab, elranatamab, and talquetamab have also been added to the clinical armamentarium.

• GPRC5D-Directed Therapies: G protein-coupled receptor family C group 5 member D (GPRC5D) has emerged as a prominent immunotherapeutic target. GPRC5D-directed CAR-T cell therapy achieved a pooled ORR of 89% (95% CI: 84–92) and CR rate of 50% (95% CI: 32–69). Critically, among patients with BCMA-relapsed/refractory disease, subsequent GPRC5D-directed CAR-T achieved an ORR of 82% (95% CI: 66–91) and CR rate of 35%, establishing antigen-switching as a viable strategy following anti-BCMA failure. Talquetamab, a GPRC5D-targeting bispecific T cell engager, has similarly been approved in this setting.

• BCL-2 Inhibition: Venetoclax, a selective inhibitor of the anti-apoptotic protein BCL-2, has demonstrated activity in relapsed/refractory MM patients harboring the t(11;14) translocation, which serves as a predictive biomarker for response. Clinical studies combining venetoclax with dexamethasone and/or proteasome inhibitors have shown promising results, and venetoclax has been incorporated into management guidelines as a treatment option for this molecularly defined MM subset.

• FcRH5 (FcRL5) as an Emerging Target: Fc receptor-like protein 5 (FcRH5, also known as FcRL5) has been identified alongside BCMA and GPRC5D as a cell-surface transmembrane protein expressed by plasma cells and a target for immunotherapeutic development, with antibody-drug conjugates and bispecific T cell engagers directed against this antigen in clinical development for relapsed/refractory MM.

Overcoming Limitations in Current Multiple Myeloma Treatment Approaches

Multiple myeloma treatment has advanced substantially with proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and novel agents, yet significant challenges persist across patient populations and disease stages. The expanding therapeutic landscape has made drug selection and sequencing increasingly complex, particularly as patients progress through multiple lines of therapy.

• Resistance to CD38-directed antibody therapy remains a critical obstacle. Daratumumab and isatuximab exert efficacy through multiple mechanisms — including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, apoptosis, and immunomodulatory effects — but resistance emerges, and the shift toward front-line daratumumab use is expected to increase the proportion of patients who are CD38-antibody refractory after first-line treatment.

• High-risk cytogenetics confer persistently poor prognosis. Genetic features such as t(4;14) and del17p are associated with worse outcomes. Bortezomib has frequently been associated with improved survival in these subgroups, whereas thalidomide maintenance has sometimes been associated with shorter survival. Achieving outcomes in high-risk patients that approximate those of standard-risk patients has remained difficult, and studies have been limited by inadequate sample size.

• Triple-class refractory disease represents a major unmet need. Patients refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies have limited options; agents such as selinexor and belantamab mafodotin have been developed to address this gap, but the choice and sequencing of therapies in this setting has become increasingly complex.

• Bispecific antibody toxicities require ongoing management. Cytokine release syndrome occurs in up to two thirds of patients receiving bispecific antibodies. BCMA-targeting bispecific antibodies in particular cause profound B-cell and plasma cell depletion, resulting in near-universal hypogammaglobulinemia, and infection is the leading cause of nonrelapse mortality in this setting. Cytopenias — including neutropenia and lymphopenia — further elevate infection risk during the first 6 months of therapy.

• Managing elderly and frail patients poses distinct challenges. Approximately one half of the multiple myeloma patient population is over 70 years at diagnosis. Determining frailty prior to treatment initiation is critical for establishing therapy intensity and transplant eligibility, and dose modifications are necessary to minimize toxicity while preserving the benefits of continuous therapy in this population.

GSK's Broader Strategic Play in T Cell Engager Technology

Beyond multiple myeloma, the trispecific T cell engager (TCE) mechanism of action is being explored across solid tumor indications, driven by efforts to improve tumor selectivity and overcome the immunosuppressive tumor microenvironment. The dual tumor-associated antigen (TAA) targeting architecture of trispecific antibodies is being adapted to address the central challenge in solid oncology: the absence of truly tumor-exclusive antigens.

• Colorectal Cancer (CRC): A tandem trispecific T cell engager (TriTE) targeting CD3, EGFR, and EpCAM has been developed and characterized for CRC. The intervention model employs a CD3-specific scFv flanked by anti-EGFR and anti-EpCAM single-domain V antibodies, enabling bivalent bispecific targeting of double-positive tumor cells. In vitro, this construct improved potency up to 100-fold against double-positive HCT116 cells compared to single-positive cells, and significantly prolonged survival in vivo in preclinical models.

• Non-Small Cell Lung Cancer (NSCLC): A conditional dual-TAA-targeting TriMab TCE using an anti-ROR1 anchoring arm paired with affinity-modulated anti-EGFR active arms and an anti-CD3 domain has been evaluated in NSCLC. The intervention model is designed as an AND-gated system, where the non-active anchoring arm (anti-ROR1) does not independently form an immunological synapse, but enables selective elimination of ROR1/EGFR double-positive NCI-H358 cells while sparing single-positive normal tissue, demonstrated in both in vitro and in vivo mouse xenograft models.

• Breast, Lung, and Colorectal Cancer (Combination Model): A combination intervention model has been explored in which trispecific T cell engagers (TriTE) are co-administered with a bispecific antibody (AxF scFv) that dually blocks PD-L1 and TGF-β to counteract tumor microenvironment-mediated immunosuppression. In breast, lung, and CRC models, this combination significantly boosted T cell activation and cytotoxic response. In vivo, the EpCAMxCD3×EGFR TriTE combined with AxF (scFv) delayed CRC tumor growth and significantly enhanced survival compared to trispecific antibody monotherapy.

• Generalizable Solid Tumor Framework (TriMab Platform): The TriMab modality has been demonstrated as a generalizable platform, with anti-HER2 mAbs targeting different binding epitopes validated as anchoring arms, supporting broader applicability across HER2-expressing solid tumors. The platform exhibits a favorable developability profile and mAb-like pharmacokinetic properties in human neonatal Fc receptor transgenic mice.

GSK's Trispecific Bet: A New Era for Multiple Myeloma?

GSK's recent acquisition of a preclinical trispecific T cell engager program for multiple myeloma marks a pivotal moment in the ongoing evolution of cancer immunotherapy. This move signals a clear intent to push the boundaries of T cell-mediated therapies, particularly in a disease where significant progress has been made but substantial unmet needs persist.

Current BCMA-directed bispecific antibodies, such as teclistamab, have revolutionized the treatment of relapsed/refractory multiple myeloma, demonstrating impressive overall response rates and deep remissions. However, their clinical utility is often tempered by a challenging safety profile. Studies consistently report high incidences of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), requiring careful monitoring and management. Furthermore, a notable proportion of patients experience severe infections and hypogammaglobulinemia, necessitating prophylactic measures and immunoglobulin supplementation.

The strategic implication of GSK's investment is clear: to develop a next-generation T cell engager that can deliver comparable or enhanced efficacy with a significantly improved safety profile. If this trispecific candidate can indeed mitigate the severe immune-related toxicities and infection risks associated with current bispecifics, it could redefine the standard of care for multiple myeloma. This would not only offer a more tolerable treatment option for patients but also provide GSK with a crucial competitive edge in a crowded therapeutic landscape.

However, the path to clinical success is fraught with inherent risks. Even with a novel trispecific design, the fundamental mechanisms of T cell engagement mean that CRS and ICANS, while potentially reduced in severity, may still be considerable challenges. The risk of infections and immune suppression, a common thread across T cell-redirecting therapies, will also need careful consideration and proactive strategies. Moreover, as observed with other targeted therapies, the potential for tumor cells to develop resistance mechanisms, such as antigen downregulation, could impact long-term efficacy. GSK's continued collaboration with Chimagen Biosciences underscores a strategic commitment to external innovation, but the ultimate success of this program will hinge on its ability to translate preclinical promise into a truly differentiated clinical reality.